Does Lutein Skin Health Randomized Trial work?

Updated July 2026

Quick Answer

Lutein Skin Health Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: Therefore, we conducted this trial to investigate whether knowledge of AMD genetic risk will inform the adoption of a healthier lifestyle that could reduce the incidence of AMD later in life.

Key Takeaways

  • 01Therefore, we conducted this trial to investigate whether knowledge of AMD genetic risk will inform the adoption of a healthier lifestyle that could reduce the incidence of AMD later in life. [Addo Emmanuel K. (2026)]
  • 02Additionally, we explored the psychological impact of AMD genetic risk disclosure on individuals’ well-being. [Addo Emmanuel K. (2026)]
  • 03We hypothesized that individuals informed of a high risk of AMD are more likely to make sustained positive lifestyle changes relative to individuals with low risk or in the deferred disclosure group. [Addo Emmanuel K. (2026)]
  • 042 3 4 5 6 7 8 9 10 11 12 13 14 15 CFH ARMS2/HTRA1 The clinical management of age-related macular degeneration (AMD) imposes a significant social and financial impact on the U.S. [Addo Emmanuel K. (2026)]
The current Migaku evidence database contains 2 reusable source documents for Lutein Skin Health Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove. - Therefore, we conducted this trial to investigate whether knowledge of AMD genetic risk will inform the adoption of a healthier lifestyle that could reduce the incidence of AMD later in life. [Addo Emmanuel K. (2026); evidence level 2] - Additionally, we explored the psychological impact of AMD genetic risk disclosure on individuals’ well-being. [Addo Emmanuel K. (2026); evidence level 2] - We hypothesized that individuals informed of a high risk of AMD are more likely to make sustained positive lifestyle changes relative to individuals with low risk or in the deferred disclosure group. [Addo Emmanuel K. (2026); evidence level 2] - 2 3 4 5 6 7 8 9 10 11 12 13 14 15 CFH ARMS2/HTRA1 The clinical management of age-related macular degeneration (AMD) imposes a significant social and financial impact on the U.S. [Addo Emmanuel K. (2026); evidence level 2] - Introduction The macula is a pigmented area located at the centre of the retina, responsible for central, high-resolution colour vision. [Xu K (2026); evidence level 2] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Carotenoid Status and Psychological Impact of Presymptomatic Macular Degeneration Genetic Risk Assessment: The MAGENTA Randomized Trial
  2. Effect of carotenoids supplementation on visual function in Chinese adults free of retinal disease: protocol for the CSV double-blind, randomised, placebo-controlled trial.